Literature DB >> 25348735

siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines.

Yuwen Song1, Luyan Mu1, Xuezhe Han2, Xiaoqian Liu3, Songbin Fu4.   

Abstract

Glioma is one of the most highly angiogenic tumors, and glioma stem cells (GSCs) are responsible for resistance to chemotherapy and radiotherapy, as well as recurrence after operation. Stathmin is substantial for mitosis and plays an important role in proliferation and migration of glioma-derived endothelial cells. However, the relationship between stathmin and GSCs is incompletely understood. Here we isolated GSCs from glioma cell lines U87MG and U251, and then used siRNA targeting stathmin for silencing. We showed that silencing of stathmin suppressed the proliferation, increased the apoptosis rate, and arrested the cell cycle at G2/M phase in GSCs. Silencing of stathmin in GSCs also resulted in inhibited the migration/invasion as well as the capability of vasculogenic mimicry. The susceptibility of GSCs to temozolomide was also enhanced by stathmin silencing. Our findings suggest stathmin as a potential target in GSCs for glioma treatment.
© The Author 2014. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  glioma stem cells; invasion; stathmin; temozolomide

Mesh:

Substances:

Year:  2014        PMID: 25348735     DOI: 10.1093/abbs/gmu099

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  9 in total

1.  HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.

Authors:  Barbara Belletti; Guidalberto Manfioletti; Michela Sgubin; Silvia Pegoraro; Ilenia Pellarin; Gloria Ros; Riccardo Sgarra; Silvano Piazza; Gustavo Baldassarre
Journal:  Cell Death Dis       Date:  2022-05-03       Impact factor: 9.685

2.  Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.

Authors:  Y Otani; T Ichikawa; K Kurozumi; S Inoue; J Ishida; T Oka; T Shimizu; Y Tomita; Y Hattori; A Uneda; Y Matsumoto; H Michiue; I Date
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

3.  miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.

Authors:  Balabhadrapatruni V S K Chakravarthi; Darshan S Chandrashekar; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Satya S Pathi; Moloy T Goswami; Xiaojun Jing; Rui Wang; Rohit Mehra; Irfan A Asangani; Arul M Chinnaiyan; Upender Manne; Guru Sonpavde; George J Netto; Jennifer Gordetsky; Sooryanarayana Varambally
Journal:  Mol Cancer Res       Date:  2017-10-12       Impact factor: 5.852

4.  [Role of ovarian tumor stem-like cells sorted from human epithelial ovarian cancer SKOV3 cells in vasculogenic mimicry formation].

Authors:  Jun Liang; Huimin Xing; Xiaohua Wu; Lei Zhang; Jun Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

5.  The effect of downregulation of Stathmin gene on biological behaviors of U373 and U87-MG glioblastoma cells.

Authors:  Ping Liu; Junyan Yu; Xiangyang Tian; Jianlan Chang; Ying Zhang; Rong Zhang; Ningning Zhang; Ranxing Huang; Lulu Li; Xianli Qiao; Hongliang Guo
Journal:  Biol Res       Date:  2018-06-08       Impact factor: 5.612

6.  MicroRNA-9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF-κB signaling pathway.

Authors:  Qingla Li; Yingnan Chang; Luyan Mu; Yuwen Song
Journal:  Oncol Lett       Date:  2019-03-18       Impact factor: 2.967

Review 7.  The Cytoskeleton-A Complex Interacting Meshwork.

Authors:  Tim Hohmann; Faramarz Dehghani
Journal:  Cells       Date:  2019-04-18       Impact factor: 6.600

8.  Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo.

Authors:  Jiwen Wang; Yanli Yao; Yue Ming; Sheng Shen; Nan Wu; Jiaqi Liu; Han Liu; Tao Suo; Hongtao Pan; Dexiang Zhang; Kan Ding; Houbao Liu
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

Review 9.  Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.

Authors:  Rong Biaoxue; Cai Xiguang; Liu Hua; Yang Shuanying
Journal:  J Transl Med       Date:  2016-09-27       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.